Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT05740722

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Led by Haukeland University Hospital · Updated on 2024-01-11

300

Participants Needed

1

Research Sites

243 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis. The main question it aims to answer is: • Does NR delay disability progression in progressive multiple sclerosis? Participants will be treated with NR or placebo for 30 months,

CONDITIONS

Official Title

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with progressive multiple sclerosis (secondary SPMS or primary PPMS) using 2013 and 2017 clinical criteria
  • Aged between 18 and 65 years
  • Expanded Disability Status Scale (EDSS) score between 3 and 6.5
  • Able to perform the Timed 25-Foot Walk (T25FW) test
  • Documented disability progression during the 24 months before screening
  • With or without stable disease-modifying therapy for at least 3 months
  • Provided written informed consent to participate
Not Eligible

You will not qualify if you...

  • Diagnosed with relapsing multiple sclerosis
  • Having any neoplastic disease at baseline
  • Prior history of malignant melanoma or breast cancer
  • Being in a stable phase of progressive disease course
  • Pregnant or breastfeeding females
  • Diagnosed with dementia or other neurodegenerative disorders at baseline
  • Psychiatric or physical comorbidities that prevent study participation
  • Used high-dose vitamin B3 supplements within 30 days before enrollment
  • Confirmed genetic mitochondrial or metabolic disorders

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Haukeland University Hospital

Bergen, Norway, 5019

Actively Recruiting

Loading map...

Research Team

K

Kjell-Morten Myhr

CONTACT

Ø

Øivind Torkildsen

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis | DecenTrialz